Abiopharma

🔍 5AM Ventures V, L.P. (Executive)

Company: Entrada Therapeutics, Inc. (TRDA)

Report Date: 2026-07-30

Detailed Transactions and Holdings:

• Sold 114,756 shares of Common Stock at $6.93 per share (Direct)
  Date: 2026-07-30 | Code: S | equity_swap_involved: 0 | shares_owned_after: 2,848,310.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 1,718 shares of Common Stock at $6.85 per share (Direct)
  Date: 2026-07-31 | Code: S | equity_swap_involved: 0 | shares_owned_after: 2,846,592.00 | transaction_form_type: 4 | Footnotes: F2
• Holds 0 shares of Common Stock (Direct)
  Date: 2026-07-30 | Code: H | nature_of_ownership: By 5AM Opportunities I, L.P. | shares_owned_after: 1,093,313.00 | Footnotes: F3

Footnotes:

• F1: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.75 to $6.95 inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F2: Shares are held by 5AM Ventures V, L.P. ("5AM V"). 5AM Partners V, LLC ("5AM Partners") is the sole general partner of 5AM V. Dr. Kush Parmar, Andrew J. Schwab and Dr. Scott M. Rocklage are managing members of 5AM Partners and may be deemed to have shared voting and investment power over the shares beneficially owned by 5AM V. Each of 5AM Partners, Mr. Schwab and Dr. Rocklage disclaims beneficial ownership of the shares of Common Stock held by 5AM V, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports.
• F3: Shares are held by 5AM Opportunities I, L.P. ("Opportunities"). 5AM Opportunities I (GP), LLC ("Opportunities GP") is the sole general partner of Opportunities. Andrew J. Schwab and Dr. Kush Parmar are managing members of Opportunities GP and may be deemed to have shared voting and investment power over the shares beneficially owned by Opportunities. Each of Opportunities GP and Mr. Schwab disclaims beneficial ownership of the shares of Common Stock held by Opportunities, except to the extent of its or his pecuniary interest therein. Dr. Parmar is a director of the Issuer and files separate Section 16 reports.